Key Highlights

Risk & Performance

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Phase 2

1(33.3%)

Phase 1

1(33.3%)

Phase 4

1(33.3%)

3Total

Phase 2(1)

Phase 1(1)

Phase 4(1)

Loading network data...

Showing 3 of 3 trials

Alzheimer's Disease Acitretin Medication

Role: lead

The Early Medication Change (EMC) Trial

Role: lead

Cognitive Hyper-performance - Effects of Stimulating Substances in Chess-players

Role: lead

All 3 trials loaded